New Delhi: In a landmark achievement in India’s medical science, the first indigenously developed quadrivalent Human Papillomavirus Vaccine (QHPV) against cervical cancer is being launched in the capital today (September 1, 2022). The Drug Controller General of India (DCGI) last month granted market authorization to Serum Institute of India (SII) to develop an indigenously developed vaccine against cervical cancer.
Dr NK Arora, Chairperson, COVID Working Group, National Technical Advisory Group on Immunization (NTAGI), said that launching a Made-in-India vaccine is an exciting experience. Very happy that our daughters and granddaughters will now be able to get this much awaited vaccine.” The last vaccines that will be launched in the program. Now, Indian vaccines will be available and we hope that it will be included in the National Immunization Program for 9-14 year old girls. will be launched.”
“It is very effective and prevents cervical cancer, because in 85 percent to 90 percent of cases, cervical cancer is caused by this particular virus and this vaccine is against those viruses. So, if we can give it to our young children and daughters They are protected from infection and as a result probably do not develop cancer after 30 years.” of our requirements within our Made-in-India vaccine,” said Dr Arora.
Union Science and Technology Minister Jitendra Singh will launch the vaccine at IIC Delhi. SII CEO Adar Poonawalla will be present at the event, officials said. According to officials, the qHPV vaccine CERVAVAC has demonstrated a strong antibody response that is approximately 1,000-fold higher for all targeted HPV types and across all doses and age groups.
Cervical cancer is the second most frequent cancer in women in the age group of 15 to 44 years in India. DCGI’s approval came after CDSCO’s recommendation of the Subject Expert Committee (SEC) on Covid-19 on June 15, when Prakash Kumar Singh, Director (Government and Regulatory Affairs) at Serum Institute, applied to DCGI seeking market authorization. was. After Phase II and III clinical trials of qHPV were completed in collaboration with the Department of Biotechnology under the Ministry of Science and Technology to ensure its early availability.
(With inputs from ANI, PTI)